Seroepidemiological analysis of anti-pneumococcal surface protein A (PspA) immunoglobulin G by clades in Japanese population
Seroepidemiological analysis of anti-pneumococcal surface protein A (PspA) immunoglobulin G by clades in Japanese population
复制标题
日本人群中抗肺炎球菌表面蛋白 A (PspA) 免疫球蛋白 G 进化枝的血清流行病学分析
DOI：
10.1016/j.vaccine.2020.09.068
复制
发表时间：
2020
期刊：
影响因子：
5.5
通讯作者：
Oishi K
中科院分区：
文献类型：
--
作者：
Morino S;Kitagami E,Nakayama H;Koizumi Y;Tanaka-Taya K;Kinjo Y;Oishi K
背景肺炎球菌表面蛋白A（PspA）是新型肺炎球菌蛋白疫苗的候选者之一。自然获得的抗PspA免疫球蛋白G（IgG）的血清流行病学的分支，在广泛的年龄范围内还没有investigated.MethodsWe检查了抗PspA IgG的分支（1，2，3，4，和5）在397人血清中的浓度0-≥70岁的酶联免疫吸附试验，并确定了几何平均浓度（GMCs）的年龄组。抗PspA IgG抗体的浓度之间的关系为每个分支为每个person.ResultsGMC的抗PspA IgG是最低的，最高的，在那些年龄6-11个月，5-9岁，和20-49岁，分别为平台。在年龄> 70岁的人群中逐渐下降。对于所有分支来说，不同年龄组的GMC模式相似。相关性被发现，特别是在同一PspA家族（分支1和2或分支4和5之间）。ConclusionsOur数据表明，大多数人获得抗PspA IgG跨分支1，2，3，4，和5在儿童时期。这些结果将为分支特异性抗PspA IgG抗体的制备提供基础数据。
BackgroundPneumococcal surface protein A (PspA) is one of the candidates of the novel pneumococcal protein vaccines. The seroepidemiology of naturally acquired anti-PspA immunoglobulin G (IgG) by clades, across a wide range of ages has not been investigated.MethodsWe examined the concentrations of anti-PspA IgG by clades (1, 2, 3, 4, and 5) in 397 sera from persons aged 0–≥70 years by enzyme-linked immunosorbent assay, and determined the geometric mean concentrations (GMCs) by age group. The relationships between concentrations of anti-PspA IgG antibody for each clade for each person were also assessed.ResultsGMC of anti-PspA IgG was lowest, highest, and plateaued in those aged 6–11 months, 5–9-years, and 20–49 years, respectively. It gradually declined in those aged > 70 years. GMCs patterns in different age groups were similar for all clades. Correlations were found especially within the same PspA family (between clades 1 and 2 or clades 4 and 5).ConclusionsOur data suggested that most people acquired anti-PspA IgG across clades 1, 2, 3, 4, and 5 during childhood. These results would be a fundamental data of clade-specific anti-PspA IgG antibodies.